Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
73 participants
OBSERVATIONAL
2018-02-09
2021-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
OCT and Early Cognitive Impairment in Multiple Sclerosis
NCT04153773
Optical Coherence Tomography and Optic Neuritis (OCTON)
NCT02573792
Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis
NCT01596881
Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct
NCT01024985
Oct-A and Perimetry in Multiple Sclerosis
NCT07175324
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This will be a prospective cross-sectional, non-interventional study; total recruitment will be 200 subjects. Recruitment will be stratified to enroll at least 50 subjects currently taking Lemtrada and 50 subjects with a documented diagnosis of ON. The study will enroll subjects primarily from practices in the Tampa Bay Area and adjacent counties. It is a planned non-interventional study; subjects will be followed by their neurologist and the study ophthalmologist and will receive standard of care. All subjects will have the ophthalmological examination and diagnostic measures, by the Principal Investigator, Dr. Grace Levy-Clarke, at Tampa Bay Uveitis Center.
Study Duration: The study duration will be 24 months, with an interim analysis at 50% recruitment status.
There are two primary aims of this longitudinal observational study:
1. To determine whether atrophy within specific retinal layers over time is associated with clinical neurological progression of MS
2. To determine whether an ON history affects the relationship described in aim # 1
Eye Exam: Subject will have an eye exam, including:
Visual Acuity Testing Color Vision Testing Automated perimetry/Peripheral Vision Testing Completing the National Eye Institute Visual Functioning Questionnaire (NEI/VFQ) Slit Lamp Examination Measurement of Intraocular Pressure (IOP) Dilated Fundus Examination (Ophthalmoscopy) Fundus Photography Optical Coherence Tomography: RNFL and Macular OCT
Neurologic Assessments: Must be performed no more than 60 days prior to screening/assessment Day 0 Ophthalmic Assessments
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pregnant women will be excluded by self declaration
* Male or female
* A diagnosis of MS, that meets the 2010 Revised McDonald Diagnostic Criteria
* A visual acuity of 20/400 or better in at least one eye
Exclusion Criteria
* Advance glaucoma with optic nerve damage
* Any optic neuropathy not diagnosed as ON associated with MS
* A diagnosis of Macular Degeneration
* Any previous ocular trauma
* Any medical history of a cerebrovascular accident
* Any planned ocular or systemic elective surgery during study duration
* Any contraindication to a comprehensive dilated ophthalmic examination
* Inability to give informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tampa Bay Uveitis Center, LLC
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Grace Levy-Clarke, M.D.
Role: PRINCIPAL_INVESTIGATOR
Tampa Bay Uveitis Center, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tampa Bay Uveitis Center
New Port Richey, Florida, United States
Tampa Bay Uveitis Center
Tampa, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TBUC10022017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.